Aggregator
Europe must seize the moment to lead on free and open science
How should I respond to race-based exclusion in my lab?
Europe as science superpower: what it will take to rival the US and China
Silicon Valley’s vision for global AI is flawed: each country needs its own blueprint
Do not leave fungi out of impact assessments
The halo effect: how academic hierarchy undermines peer review and enables fraud
Academic success still assumes uninterrupted careers
Nepal’s new science ministry must strengthen scientific capacity
This emerging treatment is helping people avoid knee replacement surgery
A minimally invasive treatment called GAE is helping people with chronic knee pain get back to gardening, cycling, and other activities without undergoing knee replacement surgery. Early studies suggest the procedure can provide years of relief by reducing inflammation inside the joint.
Scientists say most people need more protein than current guidelines suggest
A new review suggests that doing more exercise and eating more protein than current minimum recommendations may help people stay stronger, sharper, and more independent as they age. The goal isn't building a beach body—it's extending healthspan and maintaining the ability to fully enjoy life for decades longer.
A common vitamin could help fight one of the deadliest brain cancers
A clinical trial is exploring whether high doses of vitamin B3 could give patients with glioblastoma a better chance against the aggressive brain cancer. Scientists found that niacin may help revive immune cells that tumors shut down, allowing them to attack cancer more effectively. Early results have been promising, with patients showing significantly better progression-free survival than expected.
Exclusive: NSF slashes research programs to support new tech initiative, insiders say
Unexpected shift in funds has meant sharp drop in grants this fiscal year
Butterfly that barely ages could help unlock longevity secrets
Scientists discovered that Heliconius butterflies have evolved an extraordinary lifespan, living several times longer than closely related species. Even more surprising, some show little sign of physical decline as they age. Their unusual pollen-feeding lifestyle may play a role, but the research suggests deeper evolutionary changes are also helping them stay healthy for longer.
NERINE reveals rare variant associations in gene networks across phenotypes and implicates an SNCA-PRL-LRRK2 subnetwork in Parkinson's disease
Studying the genetic basis of human phenotypes involves two primary strategies. Model-system experiments generate interpretable gene networks but do not establish relevance to human disease. In contrast, statistical genetics identifies variant- and gene-level associations but cannot test mechanistic models. Here, we bridge these approaches by introducing NERINE, a hierarchical model-based rare variant association test that incorporates gene network topology while remaining robust to network...
Oral GLP-1 receptor agonist promotes astrocyte-neuron lactate and lipid transfer with neuroprotective effects
Glucagon-like peptide-1 receptor (GLP-1R) activation is widely assumed to regulate the metabolic disorder in Alzheimer's disease (AD). However, direct evidence for this hypothesis is lacking, and currently, there is no oral GLP-1R agonist with effective blood-brain barrier-penetrating ability. Here, we show that a candidate peptide, OHP2, an oral GLP-1R agonist with blood-brain barrier permeability, exhibits promising therapeutic potential for AD. OHP2 primarily activates GLP-1R on astrocytes,...
Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
No abstract
PARylation in Parkinson's disease: a bridge between Lewy body formation and neuronal cell death
Poly-ADP-ribosylation (PARylation), catalyzed by the enzyme PARP1, involves the addition of poly-ADP-ribose polymers (PAR) and has been associated with α-synuclein aggregation in Parkinson's disease (PD) models. This study aimed to unravel the role of PARylation in α-synuclein aggregation and neuronal cell death in the complex environment of post-mortem human PD brains. Using high-resolution imaging and 3D reconstruction analysis, we observed that PAR accumulate in the cytoplasm in regions...
SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease
Cells release heterogeneous extracellular vesicles and particles (EVPs) into circulation, carrying RNA and proteins that reflect their origin. Recently, brain-derived EVs have gained significant attention as non-invasive biomarkers for Alzheimer's disease (AD). Here, we identified sub-50nm extracellular nanoparticles in human brain and blood that lack the hallmarks of small EVs, exosomes, exomeres, and supermeres but are enriched for brain-specific markers, hereafter termed small EPs or...
Trained immunity in the treatment for haematological malignancy
Trained immunity, an emerging treatment strategy, confers long-term anti-tumour memory by modulating epigenetic and metabolic reprogramming of innate immune cells, offering a novel pathway for immunotherapy of haematological malignancies. This article systematically outlines the mechanisms by which inducers such as β-glucan, Bacille Calmette-Guérin (BCG) and cytokines train key effector cells including macrophages and natural killer (NK) cells. It further analyses how ageing-encompassing both...
Persistence of memory: lifespan dynamics of the human antiviral antibody reactome
The human antiviral antibody reactome provides a cumulative molecular record of immune exposures. Using high-resolution VirScan profiling, we compared epitope-level antibody responses across early childhood and adulthood. Infants are born with maternal IgG antibodies, but these antibodies decay rapidly and are replaced by endogenous responses to ~22 new viral exposures within three years. Pediatric antibody reactivities remain highly dynamic until about age 7 and are broad in epitope specificity...